Amundi
CRL icon

Amundi’s Charles River Laboratories CRL Stock Holding History

Amundi’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133M Buy
773,315
+492,301
+175% +$91.3M 0.04% 382
2025
Q4 		$56.1M Sell
281,014
-29,160
-9% -$5.29M 0.02% 613
2025
Q3 		$54.3M Buy
310,174
+83,917
+37% +$13.3M 0.02% 542
2025
Q2 		$35.6M Buy
226,257
+209,910
+1,284% +$28M 0.01% 615
2025
Q1 		$2.3M Sell
16,347
-53,919
-77% -$9.04M ﹤0.01% 1116
2024
Q4 		$13.2M Buy
70,266
+16,599
+31% +$3.2M ﹤0.01% 799
2024
Q3 		$10M Sell
53,667
-4,643
-8% -$965K ﹤0.01% 847
2024
Q2 		$11.7M Buy
58,310
+608
+1% +$138K ﹤0.01% 801
2024
Q1 		$13.1M Sell
57,702
-12,888
-18% -$3.08M 0.01% 781
2023
Q4 		$15.2M Buy
70,590
+25,896
+58% +$5.09M 0.01% 762
2023
Q3 		$8.54M Sell
44,694
-22,543
-34% -$4.63M ﹤0.01% 868
2023
Q2 		$14M Sell
67,237
-109,173
-62% -$21.7M 0.01% 770
2023
Q1 		$34.5M Buy
176,410
+63,983
+57% +$14.5M 0.02% 593
2022
Q4 		$27.8M Sell
112,427
-25,753
-19% -$5.62M 0.02% 632
2022
Q3 		$29.8M Sell
138,180
-55,123
-29% -$11.9M 0.02% 613
2022
Q2 		$40.7M Buy
193,303
+49,086
+34% +$12M 0.03% 483
2022
Q1 		$43.6M Buy
144,217
+4,915
+4% +$1.52M 0.03% 493
2021
Q4 		$49M Sell
139,302
-51,448
-27% -$20M 0.03% 481
2021
Q3 		$78.7M Buy
190,750
+35,082
+23% +$14.6M 0.06% 343
2021
Q2 		$57.6M Buy
+155,668
New +$52M 0.04% 409

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amundi's CRL Position: Q1 2026 in Review

Amundi increased its Charles River Laboratories (CRL) stake by 175% in Q1 2026, buying an estimated $91.3M and bringing the position to 773,315 shares worth $133M. The position accounts for 0.04% of the portfolio, ranked #382.

Amundi first reported a position in CRL in Q2 2021 and has held it in 20 quarters since. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Amundi held 773,315 shares of Charles River Laboratories worth $133M as of Q1 2026.
  • Amundi bought 492,301 Charles River Laboratories shares in Q1 2026, an estimated $91.3M.
  • Charles River Laboratories made up 0.04% of Amundi's portfolio in Q1 2026, its #382 holding.
  • Amundi first reported a position in Charles River Laboratories in Q2 2021 and has held it in 20 quarters since.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.